CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Direct thrombin inhibitor
Updated · Methodology
Mechanism
Dabigatran etexilate is a substrate of the efflux transporter P-glycoprotein (P-gp), and P-gp inhibitors raise dabigatran blood levels (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Cobicistat inhibits P-gp and other transporters, and according to its SmPC it can raise dabigatran levels in the same way as other strong P-gp inhibitors (cobicistat SmPC, EMA). In a study with darunavir/cobicistat 800/150 mg, the area under the concentration-time curve (AUC) of dabigatran rose by 164% after a single dose of the combination; with once-daily dosing, AUC rose by 88% and peak levels by 99% (darunavir/cobicistat/emtricitabine/tenofovir alafenamide SmPC, EMA). The kidneys clear most of the dabigatran unchanged (dabigatran SmPC, EMA), and cobicistat lowers estimated creatinine clearance because it inhibits tubular secretion of creatinine (cobicistat SmPC, EMA).
Symptoms
The main risk is bleeding: dabigatran raises the risk of hidden or overt bleeding in any tissue or organ, and major bleeding can lead to disability or death (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Common events are nosebleeds, gastrointestinal bleeding, skin bleeding, blood in the urine and anaemia; less common are coughing up blood, bleeding into joints and intracranial bleeding (dabigatran SmPC, EMA). Hidden bleeding shows as an unexplained fall in haemoglobin, haematocrit or blood pressure (dabigatran SmPC, EMA).
Management
The combination is contraindicated. The EU cobicistat SmPC contraindicates dabigatran by name, as do the SmPCs of the tablets combining cobicistat with atazanavir, with darunavir and with elvitegravir, emtricitabine and tenofovir alafenamide (SmPCs of cobicistat and of these products, European Medicines Agency, EMA). The dabigatran SmPC does not name cobicistat, but it does not recommend dabigatran with protease inhibitors such as ritonavir and its combinations with other protease inhibitors. This applies to cobicistat regimens, because cobicistat on its own is taken only with atazanavir or darunavir (dabigatran and cobicistat SmPCs, EMA). Two documents are softer. The darunavir/cobicistat/emtricitabine/tenofovir alafenamide SmPC requires clinical monitoring and a dose reduction with dabigatran (SmPC of this product, EMA). According to the US cobicistat label, with atazanavir the dabigatran dose depends on the indication and kidney function, and with darunavir no dose change is needed (cobicistat label, US Food and Drug Administration, FDA). Cobicistat lowers estimated creatinine clearance, so take this into account when clearance guides the doses of other drugs (cobicistat SmPC, EMA). If dabigatran and cobicistat have nevertheless been taken together, monitor the patient closely for signs of bleeding or anaemia (dabigatran SmPC, EMA). If haemoglobin, haematocrit or blood pressure falls without explanation, look for the bleeding site, and stop dabigatran if bleeding occurs (dabigatran SmPC, EMA). For adults with life-threatening or uncontrolled bleeding who need rapid reversal of dabigatran, the specific reversal agent idarucizumab is available (dabigatran SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Dabigatrán etexilato (EU/1/08/442), sección 4.3 (2025)– EMA, Pradaxa 110 mg cápsulas duras (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08442005, información del producto de la EMA actualizada 24/11/2025, secciones 4.3, 4.4, 4.5, 4.8 y 5.2
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)
- EMA: Ficha técnica: Cobicistat, Tybost (EU/1/13/872), sección 4.3 (2026)– EMA, Tybost 150 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida, Genvoya (EU/1/15/1061), sección 4.3 (2026)– EMA, Genvoya 150 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151061001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat/emtricitabina/tenofovir alafenamida, Symtuza (EU/1/17/1225), sección 4.5 (2026)– EMA, Symtuza 800 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1171225001, consultada 21.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5